What is Trip?
Trip operates at the intersection of the beverage industry and the burgeoning mental wellness market. By crafting a sophisticated range of drinks, oils, and gummies, the company provides a compelling alternative to traditional alcohol and high-sugar soft drinks. Its market position is defined by a commitment to flavour-forward profiles and the integration of natural ingredients designed to foster calm and balance. As consumer preferences shift toward health-conscious consumption, Trip has effectively captured a demographic seeking functional benefits without compromising on taste or lifestyle aesthetics.
The company's growth trajectory is supported by a robust product ecosystem that leverages the rising demand for adaptogenic solutions. By positioning itself as a lifestyle brand rather than a mere beverage manufacturer, Trip has successfully cultivated a loyal consumer base, establishing a significant footprint in the UK market and setting the stage for broader international expansion.
How much funding has Trip raised?
Trip has raised a total of $52M across 2 funding rounds:
Unspecified
$12M
Unspecified
$40M
Unspecified (2022): $12M with participation from Maria Raga and Christian Angermaye
Unspecified (2025): $40M, investors not publicly disclosed
Key Investors in Trip
Maria Raga
An experienced executive and investor known for supporting high-growth consumer brands and scaling digital-first enterprises.
Christian Angermayer
A prominent entrepreneur and investor with a focus on life sciences, biotechnology, and innovative consumer wellness ventures.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Trip?
With the successful closure of this major enterprise-level funding, Trip is well-positioned to accelerate its operational scaling and market penetration. The strategic allocation of this capital will likely focus on enhancing supply chain efficiencies, expanding retail distribution channels, and intensifying research and development efforts to diversify its botanical product portfolio. As the company navigates its next phase of growth, the focus will remain on maintaining brand integrity while scaling to meet the increasing global appetite for functional, wellness-oriented alternatives. The infusion of capital provides the necessary runway to solidify its leadership position in the adaptogen-infused beverage category, potentially paving the way for entry into new geographic markets and the development of innovative product lines that cater to evolving consumer wellness needs.
See full Trip company page
